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The T cell co-receptor CD8αβ enhances T cell sensitivity to antigen, however studies indi-
cate CD8αα has the converse effect and acts as a co-repressor. Using a combination of
Thymic Leukemia (TL) antigen tetramer, which directly binds CD8αα, anti-CD161, and anti-
Vα7.2 antibodies we have been able for the first time to clearly define CD8αα expression on
human CD8T cells subsets. In healthy controls CD8αα is most highly expressed by CD161
“bright” (CD161++) mucosal associated invariant T (MAIT) cells, with CD8αα expression
highly restricted to theTCRVα7.2+ cells of this subset.We also identified CD8αα-expressing
populations within the CD161 “mid” (CD161+) and “negative” (CD161−) non-MAIT CD8
T cell subsets and show TL-tetramer binding to correlate with expression of CD8β at low
levels in the context of maintained CD8α expression (CD8α+CD8 lowβ ). In addition, we
found CD161−CD8α+CD8 lowβ populations to be significantly expanded in the peripheral
blood of HIV-1 and hepatitis B (mean of 47 and 40% of CD161− T cells respectively)
infected individuals. Such CD8αα expressing T cells are an effector-memory population
(CD45RA−, CCR7−, CD62L−) that express markers of activation and maturation (HLA-
DR+, CD28−, CD27−, CD57+) and are functionally distinct, expressing greater levels of
TNF-α and IFN-γ on stimulation and perforin at rest than their CD8α+CD8 highβ counter-
parts. Antigen-specific T cells in HLA-B∗4201+HIV-1 infected patients are found within
both the CD161−CD8α+CD8 highβ and CD161−CD8α+CD8 lowβ populations. Overall we
have clearly defined CD8αα expressing human T cell subsets using the TL-tetramer, and
have demonstrated CD161−CD8α+CD8 lowβ populations, highly expanded in disease set-
tings, to co-express CD8αβ and CD8αα. Co-expression of CD8αα on CD8αβ T cells may
impact on their overall function in vivo and contribute to the distinctive phenotype of highly
differentiated populations in HBV and HIV-1 infection.
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INTRODUCTION
CD8α is a cell surface glycoprotein that can be expressed either
as a disulfide-linked heterodimer together with CD8β or as a
homodimer. In contrast to CD8αβ, CD8αα is never expressed
on naïve T cells but readily induced on strongly activated T cells
(1). In humans and mice, CD8αα can be expressed on double
negative or CD4+ or CD8αβ+ CD3+ TCRαβ+ T cells whereas
CD3+ TCRγδ+ T cells and NK cells express mostly CD8αα
alone (2).
In mice, CD8αα-expressing populations are the predominant
intraepithelial lymphocyte subset of the small bowel and either
TCR γδ+ or αβ+ (3). CD8αα has also been identified as a marker
of murine memory CD8αβ TCRαβ+ cells, with affinity induced
expression in early T cell responses identifying a memory pre-
cursor population in both an LCMV (4) and Listeria model (1).
In humans, we have recently shown single-positive (SP) CD8αα
T cells (i.e., those expressing no detectable CD8β) to be exclu-
sively derived post-thymically from a naïve CD161++CD8+ T
cell pool with a predominant usage of the Vα7.2 TCR of Mucosal
Associated Invariant T (MAIT) cells (5). In addition, CD8αα has
recently been shown using the Thymic leukemia (TL) tetramer to
be expressed on human CD8αβ+ effector-memory cells (1) and
expansion of CD8α+CD8βlow cells has been described with age
(6) and in patients with HIV-1 (7), SLE (8), and Wiskott–Aldrich
syndrome (9). CD8α+CD8βlow populations have been previously
described to be either CD28+ or CD28− (8) and similar expan-
sions have been described in post-chemotherapy patients with
Hodgkins disease as a highly differentiated CD57+perforin+ sub-
set (10). In view of our recent findings of SP CD8αα expression
linked to CD161++ MAIT cells, there is a need to more defin-
itively assess human CD8αα expression in diverse human T cell
populations in both health and disease.
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The CD8αβ co-receptor binds to the MHC class I molecule,
stabilizing the interaction between the TCR and the cognate
peptide-MHC-I complex (11), triggering T cell activation through
intracellular interaction of the CD8α cytoplasmic tail with the
Src-family protein kinases Lck and LAT and subsequent phospho-
rylation of the TCR-CD3 complex (12). CD8 T cells vary by several
orders of magnitude in their sensitivity to peptide antigen bound
to MHC-I (13, 14). This is determined on the T cell side by the TCR
affinity for the peptide-MHC-I complex, the level of TCR expres-
sion, TCR valency, accessory/co-stimulatory molecule expression,
and CD8 αβ co-receptor expression. CD8αβ co-receptor depen-
dence varies inversely with affinity of the TCR (15–19) and very
high-affinity T cells can be activated independent of CD8αβ bind-
ing (17). T cell sensitivity is an important factor in the immune
control of viral infection (20) and may play a role in outcomes
from HIV (21).
Although both CD8αβ and CD8αα bind soluble MHC-I with
similar affinity in Biacore experiments (22) and it is the cytoplas-
mic domain of the CD8α chain which interacts with Lck/LAT,
CD8αβ enhances T cell sensitivity to cognate antigen by 100-fold
compared to cells only expressing CD8αα (23, 24). It has been
suggested that this might be explained by the fact that CD8αα
is excluded from lipid rafts. Further to this, data suggests that
CD8αα may actively inhibit T cell activation, as co-expression
on CD8αα T cells decreases sensitivity to their cognate antigen
(25), although the mechanism for this is not known. In mice,
induction of expression of CD8αα by high-affinity memory pre-
cursors is thought to prevent their activation-induced cell death
and exhaustion of chronically activated effector cells as in chronic
viral infection (4).
CD8αβT cells undergo repeated rounds of cell division and dif-
ferentiation, sequentially acquiring characteristic phenotypic and
functional features of early, intermediate, and late differentiation
(26, 27). Late-differentiated cells are described as effector-memory
cells (CD45RA±, CCR7−) characterized by loss of expression of
the co-stimulatory molecules CD28 and CD27 and up-regulation
of the senescence marker CD57. They are also found to have
altered functional characteristics, with reduced production of IL-2
(and associated proliferative capacity) and increased cytotoxic-
ity and expression of inflammatory cytokines IFN-γ and TNF-α.
HIV-1 infection is associated with the development of prema-
turely senescent immune system; massive activation of the whole
CD8 T cell population is observed during acute infection (28)
and a large population of CD28−CD27−CD57+ T cells is found
within bulk CD8 T cells. In parallel to the negative implications
in aged immune systems (with increased susceptibility to infec-
tious diseases and cancer, reduced effectiveness of vaccinations,
and increased autoimmunity) (29–32), there is a significant asso-
ciation between the size of the CD28−CD27−CD57+CD8+T cell
population and HIV-1 disease progression (33). A similar observa-
tion of a large CD28−CD8 T cell population has also been made
in chronic hepatitis B (HBV) associated with higher viral load
and liver inflammation (34). Previous descriptions of expanded
CD8α+CD8βlow populations have independently described them
to be CD28− (8) and CD57+perforin+ subset (10),however there
has been no definitive study to date to bring these observations
together.
Thymic leukemia antigen is a non-classical MHC class I mole-
cule in mice. X-ray crystallography of the TL structure has demon-
strated that its antigen-binding groove is occluded and so does
not play any role in antigen presentation (35); however a number
of publications have demonstrated that it binds murine CD8αα
with much higher affinity than CD8αβ (22, 36–38). No human
homolog of TL has been identified to date; however murine TL
does bind to human CD8αα molecules with high-affinity (1) and
a TL-tetramer can be used to demonstrate expression of CD8αα at
the cellular surface of antigen-experienced human CD8αβ T cells.
Here, using both co-CD8α/CD8β antibody staining to detect
CD8αβ expression and a TL-tetramer to detect CD8αα expres-
sion we definitively describe human CD8αα expressing T cell
subsets within both the CD161++ MAIT and CD161+/CD161-
non-MAIT CD8+ T cell populations. In addition, we have shown
CD161−CD8α+CD8βlow T cells to be a late-differentiated popu-
lation that dominates in chronic infections such as those caused
by HBV and HIV-1.
MATERIALS AND METHODS
STUDY SUBJECTS
Sixteen adult healthy controls (HC), 31 patients with chronic
HBV, 23 patients with chronic HCV, and 10 patients with HIV-
1 infection were enrolled in the study. All study subjects were
recruited following informed consent and in agreement with the
Oxfordshire Research Ethics Committee. Patient demographics
are summarized in Table 1.
T CELL RECOVERY
Peripheral blood mononuclear cells (PBMCs) were isolated from
EDTA peripheral blood samples by Ficoll-Histopaque density gra-
dient centrifugation (Lymphoprep, Axis Shield). Samples not used
for immediate analysis were then frozen in a mix of DMSO (25%),
RPMI media (25%) (GibcoBRL), and fetal calf serum (50%) and
stored in liquid nitrogen prior to subsequent analysis.
ANTIBODIES
Anti-CD8α-PerCP, anti-CD3-AmCyan, anti-CD3-FITC, anti-
CD8β-APC, anti-CD4-Alexa 700, anti-IFN-γ-Alexa 700, anti-
TNF-α-PeCy7, anti-IL-2-FITC, anti-Ki67-FITC, anti-CD62L-
PeCy7, anti-CD45RA-FITC and anti-CD62L-APC, anti-CCR7
PeCy7 (BD); Anti-CD3-Pacific orange and live/dead violet fix-
able cell stain (Invitrogen); anti-CB8β-PE and anti-CD161-PE
(Beckman Coulter); anti-CD161-APC (Miltenyi).
IMMUNOFLUORESCENT STAINING
Cryopreserved PBMCs were incubated with anti-surface anti-
gen antibodies at 4°C for 20 min, washed in phosphate buffered
saline (PBS) and fixed with 1% formaldehyde in PBS. Intracellu-
lar cytokine staining was performed on cryopreserved PBMCs in
complete medium (RPMI 1640 containing 10% FCS, 1% strep-
tomycin/penicillin, and l-Glutamine), stimulated with leukocyte
activation cocktail (BD) and incubated (37°C, 5% CO2) or 4 h.
Cells were washed in PBS and stained with antibodies against
surface antigens and incubated at 4°C for 20 min. After fixa-
tion/permeabilization (FoxP3 staining kit, BD), cells were stained
with antibodies against intracellular antigens, incubated at 4°C
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Table 1 | Demographics table.
Disease No. Sex M:F Age (years) Viral load (copies/ml) ALT (U/ml) e-Antigen
status ±
CD4 count
(cells/mm3)
CMV
status ±
HBV 31 24:7 37 (21–64) 1.69×108 (0–1.7×108) 69 (12–881) 6/25 NA 20/3
HCV 23 11:12 47 (28–67) 2.25×106 (2.8×104–1.8×107) 52 (21–150) NA NA 13/7
Treated HBV 10 6:4 40 (27–49) 27 (0–100) 31 (13–63) 6/4 NA ND
HIV-1 10 ND ND 4.8×104 (758–1.9×105) NA NA 456 (51–1080) 10/0
NA, not applicable; ND, no data.
for 20 min and washed in 10% PermWash buffer (BD) in sterile
de-ionized water.
HIV-1 TETRAMER SYNTHESIS AND STAINING
HLA-B∗42:01 heavy chain was expressed in Rosetta (DE3)pLys
(Novagen), purified, and refolded around the peptide of interest
in the presence of human β2M light chain. Unrefolded heavy chain
and peptide were separated from refolded MHC:peptide monomer
complexes using FPLC prior to tetramerization of monomers and
conjugate ion to R-phycoerythrin (Extravidin PE, Sigma) to obtain
PE labeled HLA-B∗42:01 tetramers.
Antigen-specific CD8 T cell responses were studied in HLA-
B∗42:01+ HIV-1+ patients from the cohort described in Table 2.
Streptavidin-PE conjugated B42:01 tetramers were incubated with
thawed patient PBMCs at a concentration of 1 in 10 for 20 min
at room temperature. Samples were then washed in PBS and
stained with a panel of antibodies against surface antigens for
20 min at 4°C. Samples were then washed in PBS and fixed in 1%
formaldehyde prior to FACS analysis.
TL-TETRAMER STAINING
Thymic leukemia monomers, produced as previously described
(22) were tetramerized using streptavidin-PE (Molecular probes).
PBMCs from both patients and HCs were pre-incubated for
15 min at 23°C with unlabeled anti-CD8α (2.5µg/ml) (SK1; BD)
or anti-CD8β (25µg/ml) (2ST8.5H7; BD). After washing in PBS
TL-tetramer (1:100) was incubated for 10 min at 23°C. PBMCs
were then stained with a panel of antibodies (as above) to surface
antigens for 20 min at 4°C and subsequently washed in PBS and
fixed in 1% formaldehyde prior to FACS analysis.
CMV IMMUNOGLOBULIN G ELISA
Qualitative ELISA was performed on cryopreserved patient serum
samples using the Diamedix MCV IgG kit. 1:101 dilutions of serum
where made using sample diluent. Hundred microliters of stan-
dards, controls, and prepared diluted patient samples were added
to the antigen wells and incubated at 37°C for 60 min. Conjugate
was then added to each sample and incubated for a further 60 min
at 37°C. The wells were then washed and 100µl of substrate solu-
tion added to each well and incubated for a further 20 min at 37°C.
Hundred microliters of stop solution was then added and the wells
read by a plate reader at 450 nm.
FLOW CYTOMETRY
All samples prepared for FACS analysis were acquired within 24 h
of staining on an LSR II cytometer using FACS diva software (BD).
Table 2 | HIV-1 derived epitopes presented by HLA-B*42:01 alleles.
Protein Epitope name HXB2 location Amino acid sequence
p24 p24-TL9 P24-Gag180–188 TPQDLNTM L
Int Int-IM9 Int-Pol28–36 IIKDYGKQ M
Nef Nef-RM9 Nef70–78 RPQVPLRP M
Nef-TL10 Nef128–137 TPGPGVRYPL
Vpr Vpr-FL9 Vpr34–75 FPRPWLHG L
Vif Vif-HI10 Vif48–57 HPKVSSEVHI
Data was subsequently analyzed using FlowJo software (Tree star).
Gating was defined using a “Full minus one” strategy.
STATISTICAL ANALYSIS
Statistical analysis was performed using GraphPad PRISM (Graph-
Pad software) version 4. A p value of <0.05 was considered
significant.
RESULTS
DEFINING CD8β EXPRESSION LEVELS BY CD161++, CD161+, AND
CD161− CD8α+ T CELL SUBSETS
We first addressed the distribution of CD8β staining in periph-
eral blood; since we have previously shown a substantial impact of
CD161 expression on this, we analyzed the CD161++, CD161+,
and CD161− T cell populations in parallel. T cells express-
ing CD8αα were identified using a dual staining strategy with
anti-CD8α and anti-CD8β fluorochrome-labeled antibodies for
FACS analysis. As shown in both HC blood and during HBV
infection (Figure 1A), there is a broad range of CD8β expres-
sion by the CD3+CD4−CD8α+ population in peripheral blood
in the context of a single peak of CD8α expression. Further
to this, using anti-CD161 co-staining it is possible to iden-
tify three distinct populations of CD3+CD4−CD8α+ T cells.
The SP CD8αα (CD8α+CD8βneg) population is exclusive to the
CD161++MAIT cell population as demonstrated previously (5)
and in the HC shown (Figure 1B). The CD161++ population was
noted to be significantly reduced in chronic HBV, as previously
described (39, 40).
Within the CD161+ and CD161− populations it was
possible to identify two CD3+CD4−CD8α+ populations
based on CD8β expression (CD8βhigh and CD8βlow). The
CD161−CD8α+CD8βlow population was significantly expanded
in patients with chronic HBV and HIV-1 compared to HCs
(Figure 1C). Importantly, CD161−CD8α+CD8βlow T cells
expressed an αβ and not a γδ TCR (data not shown). The clone
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FIGURE 1 | Distinct CD8β expression levels are demonstrated on
CD161++, CD161+, and CD161−CD8α+T cell subsets. (A) Co-staining
of PBMCs with anti-CD8α and anti-CD8β antibodies identifies a range of
CD8β expression by CD3+CD4−CD8α+T cells in both a HC and patient
with HBV. (B) Distinct CD8βhigh, CD8βlow, and CD8βneg populations are
demonstrated based on the level of CD161 expression (marked on the
vertical gates on FACS plots as++/±). Representative FACS plots of both
HC (n=16) and patients with chronic HBV (n=31) shown. (C) The size of
the CD161−CD8α+ CD8βlow T cell population as a percentage of the
CD161−CD8α+ population is compared between HCs and patients with
chronic HBV, HCV, and HIV-1 infections. (*p<0.05, **p<0.001, One-way
ANOVAs).
of CD8β antibody used (2ST8.5H7) binds to an epitope on
CD8β which requires expression of both the CD8α and CD8β
chains. Co-staining with a separate CD8α antibody allows for
identification of populations with maintained CD8α but reduced
CD8αβ expression. By this indirect method, we conclude that the
CD8α+CD8βlow population expresses a mixture of CD8αα and
CD8αβ molecules on the cell surface due to relative levels in CD8α
and CD8β expression.
We found no association between the proportion of
CD161−CD8α+CD8βlow T cells and disease activity in either
chronic HBV or HIV-1 infections (Figure 2). Additionally
we did not find an association between the proportion of
CD161−CD8α+CD8βlow T cells and CMV seropositivity, so we
were able to exclude this as responsible for the differences in
CD161−CD8α+CD8βlow populations observed in diseased vs.
healthy cohorts (Figure 3).
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FIGURE 2 | CD161−CD8α+CD8β−T cell populations develop
independent of clinical status in chronic HBV and HIV-1 infections.
(A) Analysis of the correlation between the size of the
CD161−CD8α+CD8βlow T cell population and patient age/viral load
(Pearson) and comparison of the size of the CD161−CD8α+CD8βlow
population, as a proportion of the CD161−CD8α+ population, between
patients e-antigen positive and e-antigen negative patients (Mann
Whitney test) in chronic HBV infection. (B) Analysis of the % of
CD161−CD8α+CD8βlow T cells as a proportion of the CD161−CD8α+
population in patients with treated with chronic HBV compared to HC
(*p<0.05, unpaired t test). (C) Correlative analysis between the size of
the CD161−CD8α+CD8βlow T cell population as a proportion of the
CD161−CD8α+ population and viral load/CD4 count in HIV-1 infection
(Pearson).
THE CD161−CD8α+CD8βLOW T CELL POPULATION EXPRESSES HIGH
LEVELS OF CD8αα
To confirm that CD161−CD8α+CD8βlow T cells co-expressed
CD8αα, we used a TL-tetramer which binds to both CD8αα and
CD8αβ; this demonstrated, as previously, that following CD8αβ
blockade using the anti-CD8β antibody clone 2ST8.5H7 and an
anti-CD8α antibody as a negative control to completely block
CD8αα binding, TL-tetramer staining is specific to the CD8αα
population in humans (Figure 4A) (1). Previous experiments
have validated this method to identify CD8αα and CD8αβ co-
expressing cells using dual staining with a labeled CD8β antibody
and TL-tetramer (22, 41).
We subsequently demonstrated, using the TL-tetramer, that
in HC CD8αα is highly expressed on the CD161++ MAIT
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FIGURE 3 | CD161−CD8α+CD8βlow population is not related to CMV
status. Cumulative data comparing the % of CD161−CD8α+CD8β low
cells as a proportion of CD161−CD8α+T cells in healthy controls and
patients with HCV based on CMV status (Mann Whitney test).
cell subset of PBMCs (Figure 4B). This is in keeping with
our previous data using dual CD8α and β staining which
found the SP CD8αα (CD8α+CD8βneg) population in humans
to be restricted to this subset (5). In addition we observed
that within the CD161++ CD8+ population, CD8αα was
almost exclusively expressed by the Vα7.2+CD161++ T cells
(Figure 4C).
Using the TL-tetramer, we further investigated CD8αα expres-
sion by the CD161−CD8α+CD8βlow population in patients with
chronic viral infection. In comparison with HC, where CD8αα
is expressed mainly by the CD161++ cells, in patients with
chronic HBV, HCV, and HIV-1 we found a significant number
of TL-tetramer positive cells among the CD161+ and CD161−
non-MAIT CD8+ T cell populations (Figure 4D). Further-
more, we demonstrated a clear correlation between the pro-
portion of CD161−CD8βlow T cells and the TL-tetramer+ T
cells in these chronically infected patients (Figure 4E) indicat-
ing that the CD8α+CD8βlow population identifies a population
of CD8αα-expressing CD8αβ T cells.
CD8αα-EXPRESSING CD161−CD8α+CD8βLOW T CELLS ARE AN
EFFECTOR-MEMORY POPULATION
We next characterized the phenotype of the CD161−CD8α+
CD8βlow population. Using FACS analysis we were able to
show that in comparison the CD161−CD8α+CD8βhigh pop-
ulation, CD161−CD8α+CD8βlow T cells were mostly CCR7−
and CD62L− in the peripheral blood of both HC and patients
with chronic HBV, HCV, and HIV-1 infections (Figures 5A,B).
In HC and in chronic HBV infection there was significantly
lower expression of CD45RA by CD161−CD8α+CD8βlow com-
pared to CD161−CD8α+CD8βhigh T cells, but significance was
not met in the same comparison in patients with chronic HCV
and HIV-1 infections, indicating that they may have re-expressed
CD45RA – a recognized phenomenon of late-differentiated
cells (42).
CD8αα-EXPRESSING CD161−CD8α+CD8βLOW T CELLS EXPRESS
MARKERS OF LATE DIFFERENTIATION AND ACTIVATION
We investigated the differentiation state of the CD8αα-expressing,
CD161−CD8α+CD8βlow peripheral blood T cell population and
demonstrated significantly reduced expression of CD28, CD27,
and increased CD57 in HC and patients with chronic HBV and
HCV compared to the CD161−CD8α+CD8βhigh T cells. In HIV-
1 infected patients, we saw a significant difference only in the
expression of CD27 between the CD161−CD8α+CD8βlow and
CD161−CD8α+CD8βhigh T cells (Figures 6A,B). Overall this
may be explained by increased expression of CD57 and decreased
expression of CD28 by both the CD161−CD8α+CD8βlow and
the CD161−CD8α+CD8βhigh subsets. Consistent with this, CD57
expression was significantly higher in both subsets in HIV-1
patients compared to the HC (p< 0.05, one-way ANOVA).
To confirm these findings with the TL-tetramer, we repeated
the experiments using the staining protocols described above
to identify CD8αα-expressing cells. These experiments showed
that TL-tetramer+ cells in patients with chronic HBV and HIV-
1 had significantly increased CD57 expression and decreased
CD28 expression, in keeping with the observation that
CD161−CD8α+CD8βlow T cells express high levels of CD8αα
(Figures 6C,D).
To extend these findings, we addressed whether CD8αα-
expressing T cells also showed other markers of activa-
tion or exhaustion. We studied a panel of activation mark-
ers (CD69, CD25, CD38, HLA-DR) and found the late
activation marker HLA-DR to be significantly up regu-
lated on the CD161−CD8α+CD8βlow T cell population
compared to the CD161−CD8α+CD8βhigh T cell subset
(Figures 7A,B). In HIV-1 infected patients the difference between
the CD161−CD8α+CD8βlow and CD161−CD8α+CD8βhigh
T cell populations appeared to be abolished due to
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FIGURE 4 | A positive correlation is observed between CD8αα
expression and the size of the CD8α+CD8βlow population. (A)
Representative FACS data showing TL-tetramer binding to CD3+ and
CD3+CD4+T cells of peripheral blood lymphocytes. CD8αβ binding by
TL-tetramer is blocked by α-CD8β antibody clone 2ST8.5H7. Control
samples shown on histogram on right (Negative controls: unstained and
TL+ α − CD8α; Positive control; TL). Data shown from a patient with
chronic HBV. Data representative of 11 repeat experiments. (B)
Representative FACS data using TL-tetramer staining to demonstrate
CD8αα expression by CD3+CD161++/CD161+/CD161−T cells in HCs.
Data representative of three repeat experiments. (C) Representative FACS
data of TL-tetramer staining/CD8αα expression by CD3+CD161++ and
CD3+CD161++Vα7.2+T cell subsets in a HC. Data representative to three
repeat experiments. (D) Comparison of TL-tetramer expression/CD8αα
expression between CD161++/CD161+/CD161−T cell subsets in HCs
and patients with chronic HBV, HCV, and HIV-1 infections. (*p<0.05,
One-way ANOVAs). (E) Correlative analysis between the proportion of
CD3+CD161−TL-tetramer positive cells and the % of CD161−CD8βlow
cells as a proportion of the CD161−CD8α+ population in patients with
chronic HBV, HCV, and HIV-1 infections, r =0.7541, p=0.0118, Pearson.
up-regulation of HLA-DR on both subsets compared to the
HC CD161−CD8α+CD8βhigh population (p< 0.0001, one-way
ANOVA). We also found that overall there was increased
expression of the exhaustion marker PD-1 by CD161−CD8+
T cells in patients with chronic HBV and HCV compared
to HC (Figure 7C) and, importantly, consistently greater
expression by the CD161−CD8α+CD8βlow compared to the
CD161−CD8α+CD8βhigh T population in the patient groups
studied (Figure 7D).
CD8αα-EXPRESSING CD161−CD8α+CD8βLOW T CELLS ARE
FUNCTIONALLY DISTINCT FROM CD161−CD8α+CD8βHIGH T CELLS
We next compared the functionality of CD8αα-expressing
CD161−CD8α+CD8βlow and CD161−CD8α+CD8βhigh T cell
subsets. By stimulating whole PBMCs from HC and patients
with chronic HBV and HCV with PMA/Ionomycin we found
that there were significant functional differences between these
populations. The CD8αα-expressing CD161−CD8α+CD8βlow
T cell population produced significantly greater amounts of
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FIGURE 5 | CD161−CD8α+T cells are an effector-memory population. (A)
Representative FACS data comparing CCR7, CD62L, and CD54RA expression
by peripheral blood CD161−CD8α+CD8βlow and CD161−CD8α+CD8βhigh T cell
populations as demonstrated here by a patient with chronic HBV infection. (B)
Cumulative data comparing CCR7, CD62L, and CD54RA expression by
peripheral blood CD161−CD8α+CD8βlow and CD161−CD8α+CD8βhigh T cell
populations in HCs and patients with chronic HBV, HCV, and HIV-1 infections.
CD161−CD8α+CD8βhigh T cell and CD161−CD8α+CD8βlow T cells represented
on graphs by filled and unfilled shapes respectively. (*p<0.05, **p<0.001,
***p<0.0001, Wilcoxon signed rank test).
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FIGURE 6 | CD161−CD8α+CD8βlow T cells express markers of late
differentiation. (A) Representative FACS data comparing CD28, CD27, and
CD57 expression by peripheral blood CD161−CD8α+CD8βlow and
CD161−CD8α+CD8βhigh T cell populations as demonstrated by a patient with
chronic HBV infection. (B) Cumulative data comparing CD28, CD27, and CD57
expression by peripheral blood CD161−CD8α+CD8βlow and
CD161−CD8α+CD8βhigh T cell populations in HCs and patients with chronic
HBV, HCV, and HIV-1 infections. CD161−CD8α+CD8βhigh T cell and
CD161−CD8α+CD8βlow T cells represented on graphs by filled and unfilled
shapes respectively. (**p<0.001, ***p<0.0001, Wilcoxon signed rank test).
(C) Representative FACS data comparing CD57 and CD28 expression
between CD3+CD161−TL-tetramer+ and CD3−CD161−TL-tetramer – cells
in a patient with chronic HBV. (D) Cumulative data comparing CD57 and CD28
expression between CD3+CD161−TL-tetramer+ and CD3+CD161−
TL-tetramer – cells for patients with HBV, HCV, and HIV-1 infections
(**p<0.001, Wilcoxon signed rank test).
IFN-γ and TNF-α compared to CD161−CD8α+CD8βhigh T
cell population across HC and the patient groups studied,
although no difference in IL-2 production between the two
populations was identified (Figures 8A,B) (i.e., a greater num-
ber of cells were cytokine positive, it appears that on a per cell
basis – based on MFI, there is no difference between the two
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FIGURE 7 | CD161−CD8α+CD8βlowT cells express markers of activation
and exhaustion. (A) Representative FACS data comparing HLA-DR
expression between peripheral blood CD161−CD8α+CD8βlow and
CD161−CD8α+CD8βhigh T cell populations. (B) Cumulative data comparing
HLA-DR expression between CD161−CD8α+CD8βlow and
CD161−CD8α+CD8βhigh T cell populations in HCs and patients with chronic
HBV and HCV. CD161−CD8α+CD8βhigh T cell and CD161−CD8α+CD8βlow T
cells represented on graphs by filled and unfilled shapes respectively.
(**p<0.001, ***p<0.0001, Wilcoxon signed rank test). (C) Comparison of
PD-1 expression by CD8 T cells in patients with chronic HBV and HCV
infections compared to HCs (**p<0.001, One-way ANOVA). (D) Comparison
of PD-1 expression by CD161−CD8α+CD8βlow and CD161−CD8α+CD8βhigh T
cell populations in chronic HBV and HCV (**p<0.001, Wilcoxon signed rank
test).
populations). In addition, more CD161−CD8α+CD8βlow cells
expressed perforin compared to their CD161−CD8α+CD8βhigh
counterparts (Figures 8C,D). Overall these data indicate that
CD8αα-expressing CD161−CD8α+CD8βlow cells have enhanced
pro-inflammatory functionality and greater cytotoxicity com-
pared to the CD161−CD8α+CD8βhigh population; this is in
keeping with other published data on the functionality of
CD28−CD27−CD57+ CD8+ T cells (43).
ANTIGEN-SPECIFIC CD8+ T CELLS IN HIV-1 ARE FOUNDWITHIN BOTH
CD161−CD8α+CD8βHIGH AND CD8βLOW POPULATIONS
Using cryopreserved PBMC samples from patients with HIV-
1 carrying the HLA-B∗42:01 allele we investigated whether
antigen-specific CD8 T cells were found within both the
CD161−CD8α+CD8βhigh and CD161−CD8α+CD8βlow popu-
lations using HLA-B∗42:01-peptide tetramers (see Table 2 for
details of epitopes). In studying the distribution of antigen-
specific responses between the CD161−CD8α+CD8βhigh and
CD161−CD8α+CD8βlow populations within an individual we
were able to distinguish a variable distribution of the tetramer
positive cells, despite an almost 50:50 split of the bulk
CD8 population between the CD161−CD8α+CD8βlow and
CD161−CD8α+CD8βhigh subsets (Figure 9A). Cumulative data
from the antigen-specific populations within the five patients
studied using a panel of HLA∗B42:01 tetramers (Table 2) demon-
strated that overall there is no consistent bias toward either the
CD161−CD8α+CD8βhigh or CD161−CD8α+CD8βlow popula-
tions (Figure 9B).
DISCUSSION
We have clearly defined human CD8αα-expressing T cell pop-
ulations using both anti-CD8α/anti-CD8β co-staining and a
TL-tetramer within both MAIT and non-MAIT populations.
The TL-tetramer used is clearly able to bind CD8αα on
CD8β negative cells but can also detect CD8αα on cells
expressing CD8β, as previously described (1, 22, 41). In
this study, as previously, we blocked CD8β binding through-
out to allow for specific detection of CD8αα staining on
CD8βlow cells (1). Within the MAIT cell population, we have
shown CD8αα expression to be most prominent on the Vα7.2
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FIGURE 8 | CD161−CD8α+CD8βlow T cells are functionally distinct
from CD161−CD8α+CD8βhigh T cells. (A) Representative FACS data
comparing IFN-γ and TNF-α production by CD161−CD8α+CD8βlow and
CD161−CD8α+CD8βhigh T cell populations following stimulation with PMA
and Ionomycin. (B) Cumulative data comparing percentages of IFN-γ,
TNF-α, and IL-2 positive cells within the CD161−CD8α+CD8βlow and
CD161−CD8α+CD8βhigh T cell populations in chronic HCV and HBV
(**p<0.001, ***p<0.0001 paired t test). (C) Representative FACS plots
comparing perforin expression between CD161−CD8α+CD8βlow and
CD161−CD8α+CD8βhigh T cells. (D) Cumulative data comparing levels of
perforin expression between CD161−CD8α+CD8βlow and
CD161−CD8α+CD8βhigh T cells in HCs and patients with chronic HBV
showing CD161−CD8α+ CD8βlow (**p<0.001, ***p<0.0001, Wilcoxon
ranked test).
expressing cells of this subset. Further to this we have demon-
strated CD8αα expression on both CD161+ and CD161−
subsets. We have shown CD8αα-expressing CD161−CD8αβ
(CD161−CD8α+CD8βlow) T cells are significantly increased in
patients with chronic HBV and HIV-1 infections compared
to HC and have brought together previous data to defini-
tively demonstrate expression of CD8αα on such cells is asso-
ciated with terminally differentiated effector-memory T cells
(CCR7−CD62L−CD45RA−CD28−CD27−CD57+). Consistent
with activation-induced expression of CD8αα, these T cells also
express HLA-DR.
Although the CD161−CD8α+CD8βlow T cells are also present
in HC, it is important to consider what might be driving the
significant expansion of these cells in the context of chronic HBV
and HIV-1 infections. In HIV infection, we found no association
with the proportion of CD161−CD8α+CD8βlow T cells and viral
load or CD4 count. Equally in HBV infection, there was no associa-
tion with liver inflammation (as reflected by ALT),e-antigen status,
or age of the patient. Thus the overall relationship between the
populations and pathogenesis is not yet defined. There are two pos-
sible suggestions. Firstly, the expansion of the CD8αα-expressing T
cells could be driven by inflammatory cytokines or disease activity.
This may explain the very large magnitude of the effect, which is
affecting a set of cells likely much greater than the size of the HBV-
or HIV-specific CD8+ T cell population. The lack of clear associa-
tion with disease status is not consistent with a direct causal impact,
but might be consistent with widespread changes in T cell pheno-
type reported previously (28, 33). Alternatively, the expression of
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FIGURE 9 | Antigen-specific CD8T cells in HIV-1 are
CD161−CD8α+CD8βhigh and CD161−CD8α+CD8βlow. (A) HLA-B*42:01
tetramer positive CD8 T cell responses in a individual patient with HIV-1
demonstrates antigen-specific T cells are found in both the
CD161−CD8α+CD8βlow and CD161−CD8α+CD8βhigh populations of
peripheral blood. (B) Cumulative data showing distribution of tetramer
positive cells between CD161−CD8α+CD8βhigh and
CD161−CD8α+CD8βlow T cells in patients. Data from five different patients
with responses to epitopes p24-TL9, Int-IM9, Nef-RM9, and Vpr-FL9 are
shown.
CD8αα might be linked to TCR-driven T cell maturation. This
would explain the close links seen with expression of other pheno-
typic markers, and the known regulation previously determined
in mouse models. Whereas CD8αβ TCR co-receptor is constitu-
tively expressed on naïve T cells, CD8αα is transiently induced on
strongly activated CD8αβ effector T cells (4) and its expression
can be maintained on chronically activated memory CD8 T cells,
driven by IL-15 (44, 45). Potentially therefore, a combination of
antigen-specific and “off-target” effects could explain the findings
in HBV and HIV seen here, although the differences between HCV
and these diseases still requires further exploration.
Regardless of the underlying stimulus mediating up-regulation
of CD8αα on T cells, what is its impact once expressed? In contrast
to CD8αβ, CD8αα functions as a TCR repressor and co-expression
of CD8αα on activated cells coincides with an increased thresh-
old for activation (25, 46). Consequently, CD8αα expressed on
chronically activated CD8+ T cells might prevent exhaustion of
these cells or reduce the risk for excessive or aberrant cytolytic
responses. Thus CD8αα may act like other “tuning” molecules
to aid survival, in a manner analogous to expression of KIRs or
other NK cell associated receptors on T cells (42). Indeed, pre-
vious phenotyping of CD8βlow cells would suggest this to be the
case with increased expression of CD161, CD16, CD158α, and
NKB1, although high CD161 expression on CD28+CD8βlow T
cells likely describes the MAIT cell population (47) and empha-
sizes the need for this population to be considered when analyzing
CD8αα-expressing T cells.
Similar accumulation of CD8αα-expressing CD27−CD28−
CD57+CD8+ memory T cells would be predicted in the elderly
and also in patients with autoimmune conditions (29–32). The
consequences of this on T cell sensitivity requires further study and
may reveal unique consequences, including marked “off-target”
effects for these cells in controlling chronic infections such as
HIV-1 and HBV.
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